Study Stopped
change of technique
Hyperinflation Assessment After Treatment by Lung Volume Reduction Coil
HEAT-LVRC
Impact of Reduction Lung Volume Reduction by Coil on Hyperinflation in Severe Emphysema
1 other identifier
interventional
20
1 country
1
Brief Summary
Hyperinflation Assessment After Treatment by Lung Volume Reduction Coil (HEAT-LVRC) on Hyperinflation in Severe Emphysema
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2019
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 13, 2016
CompletedFirst Posted
Study publicly available on registry
July 15, 2016
CompletedStudy Start
First participant enrolled
January 15, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 15, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
June 15, 2019
CompletedAugust 21, 2019
August 1, 2019
Same day
July 13, 2016
August 19, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Hyperinflation Assessment After Treatment
Assessed by Lung Volume Reduction Coil
3 months
Study Arms (1)
Patient with severe emphysema
OTHERPatients with severe emphysema, stable, symptomatic, not controlled despite of international recommendations treatments will have bronchoscopy
Interventions
Two sequences of 30 minutes are necessary by patient
Bronchoscopy with Heat-LVRC
Eligibility Criteria
You may qualify if:
- Severe emphysema (recent CT-scan (\< 6 mois) )
- Age \> 35 ans
- Modified Medical Research Council Scale (mMRC) \> 2
- Forced expiratory volume in one second (FEV1) post-bronchodilatator \< 45%
- Residual volume \> 175%
- Total Pulmonary capacity \> 100%
You may not qualify if:
- Forced expiratory volume in one second (FEV1) variability \> 20% after bronchodilatator
- Carbon Monoxide Diffusing Capacity (TLCO) \< 20%
- Recurrent respiratory infection Infections with clinics symptoms
- Pulmonary arterial hypertension (PAH) with Pulmonary Arterial Systolic Pressure (PAPS) estimated with echography \> 50 mm Hg
- Impossibility to walk more that 140 meter (6 min test)
- Surgery history of volume reduction or pulmonary transplantation
- Broncho-dilatation with clinic symptoms
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Larrey Hospital
Toulouse, 31000, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nicolas Guibert, MD
University Hospital, Toulouse
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 13, 2016
First Posted
July 15, 2016
Study Start
January 15, 2019
Primary Completion
January 15, 2019
Study Completion
June 15, 2019
Last Updated
August 21, 2019
Record last verified: 2019-08
Data Sharing
- IPD Sharing
- Will not share